Payment overview · 2025
General Payments
$302.71
14 reported records · 7 companies
Healthcare provider profile · identity verified
Doyce Lee Cartrett, MD
Allopathic & Osteopathic Physicians|Family Medicine · SILSBEE, TX · NPI 1437240876
Verified facts
What the public records show
CMS Open Payments records show Doyce Lee Cartrett, MD received $302.71 in general payments during 2025 across 14 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 48.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $147.80 | 48.8% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.18 | 13.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.93 | 11.5% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $20.78 | 6.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.50 | 6.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.40 | 6.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.12 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $302.71 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $147.80 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.18 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.18 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 470 | 141 |
| Metformin Hcl | Metformin Hcl | 214 | 70 |
| Ramipril | Ramipril | 192 | 65 |
| Carvedilol | Carvedilol | 191 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 161 | 58 |
| Gabapentin | Gabapentin | 155 | 50 |
| Lisinopril | Lisinopril | 149 | 51 |
| Tramadol Hcl | Tramadol Hcl | 128 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 119 | 41 |
| Furosemide | Furosemide | 114 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 108 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 33 |
| Allopurinol | Allopurinol | 96 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 33 |
| Omeprazole | Omeprazole | 94 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 31 |
| Potassium Chloride | Potassium Chloride | 85 | 28 |
| Cilostazol | Cilostazol | 83 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 76 | 25 |
| Alprazolam | Alprazolam | 74 | 24 |
| Eliquis | Apixaban | 74 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 26 |
| Ozempic | Semaglutide | 74 | 16 |
| Glimepiride | Glimepiride | 70 | 24 |
| Meloxicam | Meloxicam | 70 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 68 | 49 |
| Simvastatin | Simvastatin | 66 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 21 |
| Losartan Potassium | Losartan Potassium | 62 | 22 |
| Clonazepam | Clonazepam | 57 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 17 |
| Montelukast Sodium | Montelukast Sodium | 53 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 16 |
| Sertraline Hcl | Sertraline Hcl | 46 | 17 |
| Prednisone | Prednisone | 45 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 12 |
| Ezetimibe | Ezetimibe | 44 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 11 |
| Azithromycin | Azithromycin | 41 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 18 |
| Buspirone Hcl | Buspirone Hcl | 40 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 23 |
| Clonidine Hcl | Clonidine Hcl | 37 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 14 |
| Gemfibrozil | Gemfibrozil | 37 | suppressed |
| Lorazepam | Lorazepam | 34 | 14 |
| Levofloxacin | Levofloxacin | 32 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | 11 |
| Famotidine | Famotidine | 31 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 11 |
| Metformin Hcl Er | Metformin Hcl | 27 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 26 | 11 |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Metaxalone | Metaxalone | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $302.71 · 14 records | Bayer Healthcare Pharmaceuticals Inc. | Auvelity, JATENZO, Kerendia, Korlym, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error